JP2023545520A5 - - Google Patents

Info

Publication number
JP2023545520A5
JP2023545520A5 JP2023523077A JP2023523077A JP2023545520A5 JP 2023545520 A5 JP2023545520 A5 JP 2023545520A5 JP 2023523077 A JP2023523077 A JP 2023523077A JP 2023523077 A JP2023523077 A JP 2023523077A JP 2023545520 A5 JP2023545520 A5 JP 2023545520A5
Authority
JP
Japan
Prior art keywords
seq
pharmaceutical composition
composition according
patient
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023523077A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023545520A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/054907 external-priority patent/WO2022081799A1/en
Publication of JP2023545520A publication Critical patent/JP2023545520A/ja
Priority to JP2025109815A priority Critical patent/JP2025143343A/ja
Publication of JP2023545520A5 publication Critical patent/JP2023545520A5/ja
Pending legal-status Critical Current

Links

JP2023523077A 2020-10-14 2021-10-14 甲状腺眼疾患を治療するための組成物及び方法 Pending JP2023545520A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025109815A JP2025143343A (ja) 2020-10-14 2025-06-27 甲状腺眼疾患を治療するための組成物及び方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063091839P 2020-10-14 2020-10-14
US63/091,839 2020-10-14
US202163201978P 2021-05-21 2021-05-21
US63/201,978 2021-05-21
US202163260130P 2021-08-10 2021-08-10
US63/260,130 2021-08-10
US202163261742P 2021-09-28 2021-09-28
US63/261,742 2021-09-28
PCT/US2021/054907 WO2022081799A1 (en) 2020-10-14 2021-10-14 Compositions and methods for treatment of thyroid eye disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025109815A Division JP2025143343A (ja) 2020-10-14 2025-06-27 甲状腺眼疾患を治療するための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2023545520A JP2023545520A (ja) 2023-10-30
JP2023545520A5 true JP2023545520A5 (cg-RX-API-DMAC7.html) 2025-07-08

Family

ID=81208791

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023523077A Pending JP2023545520A (ja) 2020-10-14 2021-10-14 甲状腺眼疾患を治療するための組成物及び方法
JP2025109815A Pending JP2025143343A (ja) 2020-10-14 2025-06-27 甲状腺眼疾患を治療するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025109815A Pending JP2025143343A (ja) 2020-10-14 2025-06-27 甲状腺眼疾患を治療するための組成物及び方法

Country Status (18)

Country Link
US (10) US20220235137A1 (cg-RX-API-DMAC7.html)
EP (1) EP4228616A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023545520A (cg-RX-API-DMAC7.html)
KR (1) KR20230124550A (cg-RX-API-DMAC7.html)
CN (5) CN119792512A (cg-RX-API-DMAC7.html)
AU (1) AU2021360889A1 (cg-RX-API-DMAC7.html)
CA (2) CA3195512A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001052A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023005996A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230204A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000073A (cg-RX-API-DMAC7.html)
EC (1) ECSP23034914A (cg-RX-API-DMAC7.html)
IL (1) IL302068A (cg-RX-API-DMAC7.html)
JO (1) JOP20230075A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023004280A (cg-RX-API-DMAC7.html)
PE (1) PE20231202A1 (cg-RX-API-DMAC7.html)
TW (2) TW202228775A (cg-RX-API-DMAC7.html)
WO (2) WO2022081804A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3195512A1 (en) * 2020-10-14 2022-04-21 Vahe Bedian Compositions and methods for treatment of thyroid eye disease
JP2024531151A (ja) * 2021-08-10 2024-08-29 ビリジアン セラピューティクス, インコーポレイテッド 甲状腺眼疾患の処置のための組成物、用量および方法
CN119823995A (zh) * 2022-12-06 2025-04-15 中南大学湘雅三医院 一种靶向cd34阳性眼眶成纤维细胞的核酸适配体及其应用
CN122122186A (zh) 2023-09-06 2026-05-29 维里迪安治疗公司 抗igf-1r抗体的药物组合物
AU2024408268A1 (en) * 2023-12-17 2026-07-09 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
WO2025151496A1 (en) * 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151492A1 (en) * 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2026044000A1 (en) * 2024-08-20 2026-02-26 Ethyreal Bio, Inc. Multispecific antibodies and methods of use thereof
WO2026095974A1 (en) 2024-10-30 2026-05-07 Horizon Therapeutics Ireland Dac Methods of treating thyroid eye disease

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4949778A (en) 1987-12-16 1990-08-21 Kawasaki Steel Corporation Immersion nozzle for continuous casting
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
ES2210306T3 (es) 1994-07-20 2004-07-01 The General Hospital Corporation Sistemas de trampa para interacciones, para detectar interacciones de proteinas.
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
ES2402878T3 (es) 1999-05-05 2013-05-10 Phylogica Limited Aislamiento de moduladores biológicos a partir de colecciones de fragmentos génicos biodiversos
DE60045243D1 (de) 1999-05-26 2010-12-30 Next Biomed Technologies Nbt Oy VERFAHREN UND MATERIALIEN ZUR ERZEUGUNG VON SH3 DOMäNEN MIT ANGEPASSTEN BINDUNGSEIGENSCHAFTEN
SE0001877D0 (sv) 2000-05-22 2000-05-22 Klaus Mosbach Molecular imprinting
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
US7998681B2 (en) 2000-10-06 2011-08-16 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Diagnosis and therapy of antibody-mediated inflammatory auto-immune disorders
US8153121B2 (en) 2000-10-06 2012-04-10 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
DE10053224A1 (de) 2000-10-26 2002-05-08 Univ Goettingen Georg August Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
EP2284270A3 (en) 2000-12-13 2012-07-25 Anaphore, Inc. Method for the identification and isolation of binding polypeptides from combinatorial libraries of proteins having the scaffold structure of C-type lectin-like domains
NZ527302A (en) 2001-01-05 2006-10-27 Abgenix Inc Antibodies to insulin-like growth factor I receptor
CN1628126A (zh) 2001-08-30 2005-06-15 比奥雷克西斯药物公司 经修饰的运铁蛋白融合蛋白
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US20030206898A1 (en) * 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
MXPA04011624A (es) 2002-05-24 2005-03-07 Schering Corp Anticuerpo neutralizante humano anti-igfr.
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
WO2004031733A2 (en) 2002-10-02 2004-04-15 Catalyst Biosciences Methods of generating and screenign for porteases with altered specificity
PT1587907E (pt) 2003-01-07 2011-04-08 Dyax Corp Biblioteca de domínios de kunitz
KR20050109489A (ko) 2003-02-13 2005-11-21 화이자 프로덕츠 인크. 항-인슐린양 성장인자 i 수용체 항체의 용도
JP2007501021A (ja) 2003-05-30 2007-01-25 アレクシオン ファーマシューティカルズ, インコーポレイテッド 遺伝子操作された定常領域を含む、抗体および融合タンパク質
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
AR046639A1 (es) 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
CN101014365B (zh) * 2004-07-16 2011-04-13 辉瑞产品公司 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP2281841A3 (en) 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomarkers for pre-selection of patients for anti-IGF1R therapy
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
BRPI0611800A2 (pt) 2005-06-15 2008-12-09 Schering Corp formulaÇço estÁvel de anticorpo
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007045465A1 (en) * 2005-10-21 2007-04-26 F. Hoffmann-La Roche Ag Method for the recombinant expression of a polypeptide
WO2007062037A2 (en) 2005-11-21 2007-05-31 Laboratoires Serono Sa Compositions and methods of producing hybrid antigen binding molecules and uses thereof
US20080014203A1 (en) 2006-04-11 2008-01-17 Silke Hansen Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008005469A2 (en) 2006-06-30 2008-01-10 Schering Corporation Igfbp2 biomarker
US8603465B1 (en) 2006-08-07 2013-12-10 Merck Sharp & Dohme, Corp. Methods for treatment of polyposis
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
US20100143340A1 (en) 2006-12-13 2010-06-10 Schering Corporation Methods and compositions for treating cancer
EP2104501B1 (en) * 2006-12-13 2014-03-12 Merck Sharp & Dohme Corp. Methods of cancer treatment with igf1r inhibitors
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008079849A2 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Antibodies to insulin-like growth factor receptor
SI2185589T1 (sl) 2007-06-01 2016-04-29 University Of Maryland Baltimore Vezavna sredstva za Fc receptor konstantne regije imunoglobulina
US20110014117A1 (en) 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
KR101616758B1 (ko) 2007-12-26 2016-04-29 젠코어 인코포레이티드 FcRn에 대한 변경된 결합성을 갖는 Fc 변이체
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
JP2011525180A (ja) 2008-06-16 2011-09-15 バインド バイオサイエンシズ インコーポレイテッド 治療的標的化ナノ粒子の製作に用いるためのジブロックコポリマーで官能化された標的薬の製造方法
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
RU2011116319A (ru) 2008-09-26 2012-11-10 Шеринг Корпорейшн (US) Производство высокого титра антител
US8137933B2 (en) 2008-11-12 2012-03-20 Schering Corporation Mammalian expression vector pUHAB
EP2419136A4 (en) * 2009-04-16 2013-01-02 Merck Sharp & Dohme COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
WO2010127284A2 (en) 2009-05-01 2010-11-04 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
MX2012002651A (es) 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
WO2011057064A1 (en) 2009-11-05 2011-05-12 Brian Long Igf1r inhibitor based treatment of prostate cancer
US9045536B2 (en) * 2009-12-23 2015-06-02 Merck Sharp & Dohme Corp. Cell line 3M
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
JP5985481B2 (ja) 2010-09-01 2016-09-06 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. 抗イディオタイプ抗体の迅速な産生
UY33707A (es) 2010-11-04 2012-05-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20120201746A1 (en) 2010-12-22 2012-08-09 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
WO2012116926A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Antigen binding proteins
JP5768147B2 (ja) 2011-02-28 2015-08-26 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 一価抗原結合タンパク質
AU2012255251B2 (en) 2011-05-18 2017-06-15 University Of Florida Research Foundation, Inc. Macrocyclic therapeutic agents and methods of treatment
AU2012255920A1 (en) * 2011-05-18 2013-11-07 Merck Sharp & Dohme Corp. Therapeutic anti-IGF1R combinations
WO2012162067A2 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
TW201333039A (zh) 2011-12-30 2013-08-16 Abbvie Inc 雙可變域免疫球蛋白及其用途
CA2864432A1 (en) 2012-02-15 2013-08-22 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
EP2852685A1 (en) * 2012-03-30 2015-04-01 Merck Sharp & Dohme Corp. Igf1 biomarker for igf1r inhibitor therapy
WO2013169611A1 (en) 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Compositions and methods for treating breast cancer
EP2863947B1 (en) 2012-06-21 2018-03-07 Sorrento Therapeutics, Inc. Antigen binding proteins that bind igf1r
NZ711373A (en) 2013-03-13 2020-07-31 Bioasis Technologies Inc Fragments of p97 and uses thereof
TW201920285A (zh) 2013-04-29 2019-06-01 瑞士商赫孚孟拉羅股份公司 遏止FcRn結合之抗IGF-1R抗體及其治療血管性眼疾之用途
CA2904806C (en) * 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
CA2904805A1 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
US20210138076A2 (en) 2014-01-27 2021-05-13 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
MA39909B1 (fr) 2014-04-25 2019-05-31 Pf Medicament Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
WO2016004389A2 (en) 2014-07-03 2016-01-07 Abbvie Inc. Monovalent binding proteins
WO2016064716A1 (en) 2014-10-20 2016-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination therapy of tshr antagonist and igfr inhibitor
TWI769570B (zh) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI870335B (zh) 2015-06-12 2025-01-21 美商宏觀基因股份有限公司 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
WO2017011773A2 (en) 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11596699B2 (en) 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
EP3493845A4 (en) * 2016-08-03 2020-04-15 The Board of Trustees of the Leland Stanford Junior University INTERRUPTION OF FC RECEPTOR USE ON MACROPHAGES TO IMPROVE THE EFFECTIVENESS OF ANTI-SIRPALPHA ANTIBODY THERAPY
JP7186400B2 (ja) 2016-08-30 2022-12-09 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム ゲノム的に再コードした生物におけるセレノ-生物製剤の製造
EP3516068B1 (en) 2016-09-19 2025-04-23 University of Southern California Non-radioactive cytotoxicity assays
HRP20250482T1 (hr) * 2016-12-21 2025-06-20 Cephalon Llc Protutijela koja se specifično vežu na ljudski il-15 i njihove uporabe
CN106546800B (zh) 2017-01-25 2019-06-18 北京鸿智电通科技有限公司 一种应用于快充电源的充/放电电流检测电路
US10722589B2 (en) 2017-04-03 2020-07-28 Covagen Ag FGFR3 binding molecules
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
WO2018204872A2 (en) * 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Igf-1r monoclonal antibodies and uses thereof
CA3056573A1 (en) 2017-05-30 2018-12-06 Teijin Pharma Limited Anti-igf-i receptor antibody
SG11202002489YA (en) 2017-10-06 2020-04-29 Prothena Biosciences Ltd Anti-transthyretin antibodies
WO2019084026A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
US11208490B2 (en) * 2018-03-05 2021-12-28 Horizon Therapeutics Ireland Dac Methods for the treatment of thyroid eye disease
US20210284741A1 (en) 2018-01-24 2021-09-16 Hznp Limited Methods for the treatment of thyroid eye disease
US11208489B2 (en) * 2018-01-24 2021-12-28 Horizon Therapeutics Ireland Dac Methods for the treatment of thyroid eye disease
WO2019183523A1 (en) 2018-03-23 2019-09-26 Genentech, Inc. Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
EP4036014B1 (en) * 2018-03-28 2024-05-01 Airbus Operations GmbH Fuselage assembly for an aircraft
WO2020006486A1 (en) 2018-06-29 2020-01-02 Krystal Biotech, Inc. Compositions and methods for antibody delivery
JP6958530B2 (ja) * 2018-10-10 2021-11-02 セイコーエプソン株式会社 光学モジュールおよび頭部装着型表示装置
KR20210099073A (ko) * 2018-12-03 2021-08-11 퓨전 파마슈티칼즈 인크. 방사성면역접합체와 체크포인트 억제제의 조합 요법
SI3898668T1 (sl) * 2018-12-19 2024-02-29 Humabs Biomed Sa Protitelesa, ki nevtralizirajo virus hepatitisa B in njihove uporabe
CN111744013B (zh) 2019-03-29 2022-07-26 江苏恒瑞医药股份有限公司 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
JP2022545835A (ja) * 2019-08-28 2022-10-31 ホライゾン セラピューティクス アイルランド デジグネイテッド アクティビティ カンパニー 甲状腺眼症の治療方法
CN113402602B (zh) 2020-03-17 2022-09-23 上海祥耀生物科技有限责任公司 一种新型冠状病毒SARS-CoV-2中和性抗体及应用
WO2021243014A1 (en) 2020-05-28 2021-12-02 Horizon Therapeutics Ireland Dac Methods for the treatment of idiopathic orbital inflammation and related conditions
CA3195512A1 (en) 2020-10-14 2022-04-21 Vahe Bedian Compositions and methods for treatment of thyroid eye disease
TW202246339A (zh) 2021-03-03 2022-12-01 愛爾蘭商赫萊森治療愛爾蘭公司 治療甲狀腺眼疾的方法
EP4123454A1 (en) 2021-07-21 2023-01-25 Abb Schweiz Ag Validating component specifications for industrial automation systems
JP2024531151A (ja) 2021-08-10 2024-08-29 ビリジアン セラピューティクス, インコーポレイテッド 甲状腺眼疾患の処置のための組成物、用量および方法
JP2024532482A (ja) 2021-09-01 2024-09-05 バイオセプター (オースト) プロプライエタリー・リミテッド 免疫活性を刺激するための方法および組成物
MX2024007968A (es) * 2021-12-23 2024-07-29 Viridian Therapeutics Inc Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea.
CA3242661A1 (en) 2022-01-07 2023-07-13 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
CN118679187A (zh) 2022-01-07 2024-09-20 维里迪安治疗公司 用于治疗甲状腺眼疾病的组合物和方法
JP2025503637A (ja) 2022-01-09 2025-02-04 クリヤ セラピューティクス, インコーポレイテッド 治療用抗igf-1r抗体をコードする核酸の送達のためのベクター構築物およびそれを使用する方法
CN122003247A (zh) 2023-07-07 2026-05-08 维里迪安治疗公司 治疗活动性和慢性甲状腺眼病的方法
CN122122186A (zh) 2023-09-06 2026-05-29 维里迪安治疗公司 抗igf-1r抗体的药物组合物

Similar Documents

Publication Publication Date Title
JP2024531151A5 (cg-RX-API-DMAC7.html)
JP2022119854A5 (cg-RX-API-DMAC7.html)
JP2023093495A5 (cg-RX-API-DMAC7.html)
US20250195646A1 (en) Combinations and uses thereof
JP2024170522A5 (cg-RX-API-DMAC7.html)
RU2016130056A (ru) Способы лечения кожной инфекции путем введения антагониста il-4r
FI3810281T3 (fi) Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla
JP2022523372A5 (cg-RX-API-DMAC7.html)
RU2019112029A (ru) Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований
AU2015279212B2 (en) Topical application for an anti-HSV antibody
JP2017507954A5 (cg-RX-API-DMAC7.html)
JP2015514110A5 (cg-RX-API-DMAC7.html)
JP2012518404A5 (cg-RX-API-DMAC7.html)
IL317199A (en) Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
JP2023055904A5 (cg-RX-API-DMAC7.html)
RU2019139093A (ru) Фармацевтическая композиция на основе антитела к pd-l1 и ее применение
FI3394103T3 (fi) Anti-PD-1-vasta-aineiden ja bispesifisten anti-CD20-/anti-CD3-vasta-aineiden yhdistelmä syövän hoitoon
RU2015110635A (ru) Лечение сосудистого заболевания и его осложнений
JP2024540226A5 (cg-RX-API-DMAC7.html)
JP2024533067A5 (cg-RX-API-DMAC7.html)
JP2024515968A5 (cg-RX-API-DMAC7.html)
FI3630177T3 (fi) Hoitoparadigma anti-cd19-vasta-aineen ja venetoklaksin yhdistelmähoidolle
CN119053343A (zh) 抗tim-3抗体与抗pd-1抗体的药物组合
JP2023502398A5 (cg-RX-API-DMAC7.html)
WO2018072743A1 (zh) Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途